Our Products

Picture
Products
Lead Compound
Olatec’s pharmaceutical platform is intended to address significant unmet needs in the treatment of acute and chronic inflammatory diseases.  The Company’s lead compound, dapansutrile (lab code: OLT1177®) is a NLRP3 inhibitor in Phase 2 clinical trials in the US and Europe.  In addition to dapansutrile, Olatec’s platform includes more than 60 structurally related compounds (OLT Analogues). Based on clinical results and the expected market advantages of dapansutrile, as well as data being generated from the OLT Analogues, Olatec’s platform has the potential not only to transform and expand markets, but also to represent a new class of pharmaceuticals for the treatment of inflammatory diseases that are known to mediated by IL-1.
OLT1177® is a pharmaceutical grade of dapansutrile.  OLT1177® is a registered trademark of Olatec Therapeutics in the United States and other countries.  Olatec does not authorize other parties to use the OLT1177 trademark for their products, and will take legal action to stop other parties from mis-using OLT1177 for their products.  
 
Products currently being sold by unauthorized manufacturers claiming to offer OLT1177 have been shown to have inferior product quality, including, but not limited to, lower potency and greater impurities which may adversely impact the outcomes and safety of any preclinical scientific research.  
 
If you are interested in OLT1177® for preclinical research, please submit a request through the contact form here.